These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 39096619)

  • 1. Long-term effects of luteolin in a mouse model of nephropathic cystinosis.
    De Leo E; Taranta A; Raso R; Pezzullo M; Piccione M; Matteo V; Vitale A; Bellomo F; Goffredo BM; Diomedi Camassei F; Prencipe G; Rega LR; Emma F
    Biomed Pharmacother; 2024 Sep; 178():117236. PubMed ID: 39096619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell-Based Phenotypic Drug Screening Identifies Luteolin as Candidate Therapeutic for Nephropathic Cystinosis.
    De Leo E; Elmonem MA; Berlingerio SP; Berquez M; Festa BP; Raso R; Bellomo F; Starborg T; Janssen MJ; Abbaszadeh Z; Cairoli S; Goffredo BM; Masereeuw R; Devuyst O; Lowe M; Levtchenko E; Luciani A; Emma F; Rega LR
    J Am Soc Nephrol; 2020 Jul; 31(7):1522-1537. PubMed ID: 32503896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cystinosis (ctns) zebrafish mutant shows pronephric glomerular and tubular dysfunction.
    Elmonem MA; Khalil R; Khodaparast L; Khodaparast L; Arcolino FO; Morgan J; Pastore A; Tylzanowski P; Ny A; Lowe M; de Witte PA; Baelde HJ; van den Heuvel LP; Levtchenko E
    Sci Rep; 2017 Feb; 7():42583. PubMed ID: 28198397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Human Induced Pluripotent Stem Cells and Kidney Organoids To Develop a Cysteamine/mTOR Inhibition Combination Therapy for Cystinosis.
    Hollywood JA; Przepiorski A; D'Souza RF; Sreebhavan S; Wolvetang EJ; Harrison PT; Davidson AJ; Holm TM
    J Am Soc Nephrol; 2020 May; 31(5):962-982. PubMed ID: 32198276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cystinosin-deficient rats recapitulate the phenotype of nephropathic cystinosis.
    Hollywood JA; Kallingappa PK; Cheung PY; Martis RM; Sreebhavan S; 'Atiola RD; Chatterjee A; Buckels EJ; Matthews BG; Lewis PM; Davidson AJ
    Am J Physiol Renal Physiol; 2022 Aug; 323(2):F156-F170. PubMed ID: 35695380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dedifferentiation and aberrations of the endolysosomal compartment characterize the early stage of nephropathic cystinosis.
    Raggi C; Luciani A; Nevo N; Antignac C; Terryn S; Devuyst O
    Hum Mol Genet; 2014 May; 23(9):2266-78. PubMed ID: 24319100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intralysosomal cystine accumulation in mice lacking cystinosin, the protein defective in cystinosis.
    Cherqui S; Sevin C; Hamard G; Kalatzis V; Sich M; Pequignot MO; Gogat K; Abitbol M; Broyer M; Gubler MC; Antignac C
    Mol Cell Biol; 2002 Nov; 22(21):7622-32. PubMed ID: 12370309
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Bondue T; Khodaparast L; Khodaparast L; Cairoli S; Goffredo BM; Gijsbers R; van den Heuvel L; Levtchenko E
    Am J Physiol Renal Physiol; 2024 Jun; 326(6):F981-F987. PubMed ID: 38545650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impairment of chaperone-mediated autophagy leads to selective lysosomal degradation defects in the lysosomal storage disease cystinosis.
    Napolitano G; Johnson JL; He J; Rocca CJ; Monfregola J; Pestonjamasp K; Cherqui S; Catz SD
    EMBO Mol Med; 2015 Feb; 7(2):158-74. PubMed ID: 25586965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the transcription factor EB rescues lysosomal abnormalities in cystinotic kidney cells.
    Rega LR; Polishchuk E; Montefusco S; Napolitano G; Tozzi G; Zhang J; Bellomo F; Taranta A; Pastore A; Polishchuk R; Piemonte F; Medina DL; Catz SD; Ballabio A; Emma F
    Kidney Int; 2016 Apr; 89(4):862-73. PubMed ID: 26994576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioengineered Cystinotic Kidney Tubules Recapitulate a Nephropathic Phenotype.
    Sendino Garví E; Masereeuw R; Janssen MJ
    Cells; 2022 Jan; 11(1):. PubMed ID: 35011739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cysteamine-bicalutamide combination therapy corrects proximal tubule phenotype in cystinosis.
    Jamalpoor A; van Gelder CA; Yousef Yengej FA; Zaal EA; Berlingerio SP; Veys KR; Pou Casellas C; Voskuil K; Essa K; Ammerlaan CM; Rega LR; van der Welle RE; Lilien MR; Rookmaaker MB; Clevers H; Klumperman J; Levtchenko E; Berkers CR; Verhaar MC; Altelaar M; Masereeuw R; Janssen MJ
    EMBO Mol Med; 2021 Jul; 13(7):e13067. PubMed ID: 34165243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multisystem involvement, defective lysosomes and impaired autophagy in a novel rat model of nephropathic cystinosis.
    Krohn P; Rega LR; Harvent M; Festa BP; Taranta A; Luciani A; Dewulf J; Cremonesi A; Camassei FD; Hanson JVM; Gerth-Kahlert C; Emma F; Berquez M; Devuyst O
    Hum Mol Genet; 2022 Jul; 31(13):2262-2278. PubMed ID: 35137071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection of Cystinotic Mice by Kidney-Specific Megalin Ablation Supports an Endocytosis-Based Mechanism for Nephropathic Cystinosis Progression.
    Janssens V; Gaide Chevronnay HP; Marie S; Vincent MF; Van Der Smissen P; Nevo N; Vainio S; Nielsen R; Christensen EI; Jouret F; Antignac C; Pierreux CE; Courtoy PJ
    J Am Soc Nephrol; 2019 Nov; 30(11):2177-2190. PubMed ID: 31548351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between galectin-3 and cystinosin uncovers a pathogenic role of inflammation in kidney involvement of cystinosis.
    Lobry T; Miller R; Nevo N; Rocca CJ; Zhang J; Catz SD; Moore F; Thomas L; Pouly D; Bailleux A; Guerrera IC; Gubler MC; Cheung WW; Mak RH; Montier T; Antignac C; Cherqui S
    Kidney Int; 2019 Aug; 96(2):350-362. PubMed ID: 30928021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered mTOR signalling in nephropathic cystinosis.
    Ivanova EA; van den Heuvel LP; Elmonem MA; De Smedt H; Missiaen L; Pastore A; Mekahli D; Bultynck G; Levtchenko EN
    J Inherit Metab Dis; 2016 May; 39(3):457-464. PubMed ID: 26909499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystinosin, the small GTPase Rab11, and the Rab7 effector RILP regulate intracellular trafficking of the chaperone-mediated autophagy receptor LAMP2A.
    Zhang J; Johnson JL; He J; Napolitano G; Ramadass M; Rocca C; Kiosses WB; Bucci C; Xin Q; Gavathiotis E; Cuervo AM; Cherqui S; Catz SD
    J Biol Chem; 2017 Jun; 292(25):10328-10346. PubMed ID: 28465352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mouse model suggests two mechanisms for thyroid alterations in infantile cystinosis: decreased thyroglobulin synthesis due to endoplasmic reticulum stress/unfolded protein response and impaired lysosomal processing.
    Gaide Chevronnay HP; Janssens V; Van Der Smissen P; Liao XH; Abid Y; Nevo N; Antignac C; Refetoff S; Cherqui S; Pierreux CE; Courtoy PJ
    Endocrinology; 2015 Jun; 156(6):2349-64. PubMed ID: 25811319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of long-term cysteamine treatment in patients with cystinosis.
    Ariceta G; Giordano V; Santos F
    Pediatr Nephrol; 2019 Apr; 34(4):571-578. PubMed ID: 29260317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genistein improves renal disease in a mouse model of nephropathic cystinosis: a comparison study with cysteamine.
    De Leo E; Taranta A; Raso R; Polishchuk E; D'Oria V; Pezzullo M; Goffredo BM; Cairoli S; Bellomo F; Battafarano G; Camassei FD; Del Fattore A; Polishchuk R; Emma F; Rega LR
    Hum Mol Genet; 2023 Mar; 32(7):1090-1101. PubMed ID: 36300303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.